8D36
Crystal structure of SARS-CoV-2 fusion peptide in complex with neutralizing antibody COV44-62
Summary for 8D36
Entry DOI | 10.2210/pdb8d36/pdb |
Descriptor | Neutralizing antibody COV44-62 heavy chain, Neutralizing antibody COV44-62 light chain, Spike protein S2 fusion peptide, ... (4 entities in total) |
Functional Keywords | sars-cov-2, coronavirus, antibody, fusion peptide, neutralizing antibody, covid-19, immune system |
Biological source | Homo sapiens (human) More |
Total number of polymer chains | 3 |
Total formula weight | 48689.42 |
Authors | Yuan, M.,Lee, C.C.D.,Wilson, I.A. (deposition date: 2022-05-31, release date: 2022-07-27, Last modification date: 2023-10-18) |
Primary citation | Dacon, C.,Tucker, C.,Peng, L.,Lee, C.D.,Lin, T.H.,Yuan, M.,Cong, Y.,Wang, L.,Purser, L.,Williams, J.K.,Pyo, C.W.,Kosik, I.,Hu, Z.,Zhao, M.,Mohan, D.,Cooper, A.J.R.,Peterson, M.,Skinner, J.,Dixit, S.,Kollins, E.,Huzella, L.,Perry, D.,Byrum, R.,Lembirik, S.,Drawbaugh, D.,Eaton, B.,Zhang, Y.,Yang, E.S.,Chen, M.,Leung, K.,Weinberg, R.S.,Pegu, A.,Geraghty, D.E.,Davidson, E.,Douagi, I.,Moir, S.,Yewdell, J.W.,Schmaljohn, C.,Crompton, P.D.,Holbrook, M.R.,Nemazee, D.,Mascola, J.R.,Wilson, I.A.,Tan, J. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science, 377:728-735, 2022 Cited by PubMed Abstract: The potential for future coronavirus outbreaks highlights the need to broadly target this group of pathogens. We used an epitope-agnostic approach to identify six monoclonal antibodies that bind to spike proteins from all seven human-infecting coronaviruses. All six antibodies target the conserved fusion peptide region adjacent to the S2' cleavage site. COV44-62 and COV44-79 broadly neutralize alpha- and betacoronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants BA.2 and BA.4/5, albeit with lower potency than receptor binding domain-specific antibodies. In crystal structures of COV44-62 and COV44-79 antigen-binding fragments with the SARS-CoV-2 fusion peptide, the fusion peptide epitope adopts a helical structure and includes the arginine residue at the S2' cleavage site. COV44-79 limited disease caused by SARS-CoV-2 in a Syrian hamster model. These findings highlight the fusion peptide as a candidate epitope for next-generation coronavirus vaccine development. PubMed: 35857439DOI: 10.1126/science.abq3773 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.45 Å) |
Structure validation
Download full validation report